Views & Analysis 3 key trends shaping the immunology market From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.
News J&J ends 2018 on a high, but coming year looks shaky Johnson & Johnson (J&J) has kicked off results season with a downbeat forecast for the year as competition to some of its top products starts to have an impact on revenues.
News No US Remicade biosimilar until at least October Pfizer must wait until 180 day period ends, court fight ongoing.
News Biosimilar switching not suitable for all patients Antibodies against originator will also target biosimilar.
News Dismay but little surprise as NICE rejects Alzheimer's drugs Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face